STOCK TITAN

Exact Sciences Corp. - EXAS STOCK NEWS

Welcome to our dedicated news page for Exact Sciences (Ticker: EXAS), a resource for investors and traders seeking the latest updates and insights on Exact Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Exact Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Exact Sciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.61%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.57%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.04%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.04%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
23.04%
Tags
Exact Sciences Corp.

Nasdaq:EXAS

EXAS Rankings

EXAS Stock Data

12.95B
179.56M
1.01%
89.38%
3.49%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
US
Madison

About EXAS

exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences'​ noninvasive colon cancer screening test, visit cologuardtest.com